Hazte Socio de la SETH

Auspicios de la SETH

Síguenos en Twitter

Síguenos en Facebook

Día Mundial de la Trombosis - 13 de Octubre


Noticias científicas

Entrevista Dra. María Teresa Santos (MLTD)

Fuente: Newsletter MLTD
Abril de 2014

Dra. María Teresa SantosDr. María Teresa Santos is staff scientist at the Healt Research Institute of the University and Polytechnic Hospital La Fe in Valencia (Spain), and she is currently General Secretary of the MLTD and Vice-president of the 23rd Biennial International Congress on Thrombosis.

Being General Secretary, could you please tell us a bit about the beginnings of the MLTD?

Yes, of course. The Mediterranean League against Thromboembolic Diseases (MLTD) is a non-profit scientific society founded 46 years ago by a group of Mediterranean scientists, who were interested in thrombosis; an idea that was pioneer at that time. The first Spanish-French meeting was driven by Dr. JA Iriarte and J. Monasterio, and took place in Bilbao (Spain) in 1967. After that, the attendees decided to meet every two years. The next meeting took place in 1969 in Bilbao, too. During this meeting they decided to create an international scientific society concerning these aspects. The funding countries and their first counsellors were: Bulgaria (Dr Anastasoff), Spain (Dr J Aznar), France (Dr Samama), Greece (Dr Mandalaki), Israel (Dr De Vries), Italy (Dr de Nicola) and Turkey (Dr ON Ultin). The MLTD has grown steadily, it is currently joined by 17 countries and has established partnerships with associations and scientists from all over the world. The goal of the MLTS is to open new avenues for membership or association with additional countries, especially European and Mediterranean.

Which are the objectives and features of the MLTD?

Its main aim was, and still is, to promote scientific advances  from a multidisciplinary approach and to disseminate knowledge  on thrombosis internationally. This way, the MLTD can  help countless patients that suffer from thrombosis, the main  cause of morbidity and mortality in many countries.  
One of the MLTD most important characteristic is the  multidisciplinary of its members and congress attendees. At  the time when the society was created, and even decades later,  it was a quite uncommon feature among scientific societies,  but MLTD founding scientists realized that major scientific  progress can be achieved by creating cooperation and knowledge-  exchange bridges between people who are working in  basic laboratory research, in clinical research and those that  provide personal experience from their daily routine with  patients. Multidisciplinarity among the MLTD members  extends to medical disciplines such as haematologists, cardiologists,  neurologists, angiologists, experts in internal medicine,
gynaecologists, etc, that face thrombosis or  bleeding problems among their patients in  everyday practice.
Another characteristic of the MLTD that  also comes from its beginnings is that  International Congresses on Thrombosis  (ICT) take place in a kind and relaxed  atmosphere that tries to reflect the culture  and soul of the Organizing Country.

What can you tell us about the 23rd Biennial ICT of Valencia?

The congress will provide the latest advances in Thrombosis in different clinical scenarios, management of patients, treatments and basic research. In order to achieve these goals, we count on a distinguished group of international faculty and opinion leaders in our programme. The latest developments in thrombosis will be presented, such as the implications of thrombosis in the evolution of vascular diseases, current challenges in vein thrombosis and pulmonary embolism. The will be sessions about the advances in molecular mechanisms of platelet reactivity, new genetic factors contributing to the incidence of thrombosis, developments in antithrombotic therapy (anticoagulants and antiplatelets agents), about thrombosis in children, in pregnant women and in gynaecological pathologies, in cancer patients and in patients that show altered blood clotting factors, etc. Moreover, I am sure that the free communications presented by researchers from all over the world will constitute an important source of new scientific information. They will definitely promote, through dialogue among the attendees, the development of knowledge and exchange of experience, which always is in benefit for patients.

How would you like people to remember the 23rd Biennial ITC?

I would really like this event to be remembered as a scientific success, because the programme was very carefully prepared by the organizers. However, I would also like the attendees to remember the congress of Valencia as a kind and friendly event that favoured profitable scientific exchanges, created strong and lasting friendships and, last but not least, that allowed them to enjoy Valencia, a very lively, interesting city with a strong contrast between its historical tradition and the most vibrant trendiness.

MLTD - April Newsletterl   MLTD - 23rd Biennal International Congress on Thrombosis

23rd Biennial International Congress on Thrombosis
Valencia, Spain - 14-17 May 2014


Nuestra web utiliza cookies para ofrecerte un mejor servicio. Si continúas navegando, consideramos que aceptas su uso. Puedes visitar nuestro 'Uso de cookies' para obtener más información o cambiar tu configuración.